• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

柳氮磺胺吡啶:二、关于柳氮磺吡啶发现与研发的一些笔记

Sulfasalazine: II. Some notes on the discovery and development of salazopyrin.

作者信息

Svartz N

机构信息

King Gustaf V Research Institute, Stockholm, Sweden.

出版信息

Am J Gastroenterol. 1988 May;83(5):497-503.

PMID:2896459
Abstract

In summing up: salazopyrin is an effective drug, particularly in ulcerative colitis. Serious adverse effects are remarkably rare. Salazopyrin provoked an improvement in 75-80% of cases of UC. It is excellently adapted for long-term treatment and, in this respect, is clearly superior to corticosteroids. It prevents relapses, particularly if the dosage is increased. The main indication for corticosteroids in UC is for acute attacks early in the course of the disease and to influence allergic symptoms during the disease. For acute swelling of the rectum, local treatment with corticosteroids or salazopyrin is often effective. Adverse effects occur in about 15% of cases treated with salazopyrin. They are due primarily to hypersensitivity to the drug. With very few exceptions, they disappear spontaneously or are controlled by corticosteroids or by some other treatment. The allergic pulmonary changes may give rise to a modest dyspnea, which is not fatal. The cyanotic and the yellow-coloring of the skin are harmless side effects. As to sulfa crystals in the kidneys and the urine, for the most part, they can be avoided by simple treatment. Agranulocytosis is a rare complication in the course of treatment with salazopyrin. During the 35 yr that the drug has been used, only 14 cases have been published in the literature. Of this number, three have died, but the treatment of the agranulocytosis is known in only one of them. Nonpublished cases probably exist, but this number does not seem to be great in my experience. In comparison with many other drugs (certain chemotherapeutics and antibiotics), the frequency of serious side effects caused by salazopyrin is remarkably low.

摘要

综上所述

柳氮磺胺吡啶是一种有效的药物,尤其在治疗溃疡性结肠炎方面。严重的不良反应极为罕见。柳氮磺胺吡啶能使75%至80%的溃疡性结肠炎病例病情改善。它非常适合长期治疗,在这方面明显优于皮质类固醇。它能预防复发,尤其是在增加剂量的情况下。皮质类固醇在溃疡性结肠炎中的主要适应证是疾病早期的急性发作以及影响疾病期间的过敏症状。对于直肠急性肿胀,局部使用皮质类固醇或柳氮磺胺吡啶治疗通常有效。接受柳氮磺胺吡啶治疗的病例中约15%会出现不良反应。这些不良反应主要是由于对该药物过敏。除极少数情况外,它们会自行消失或通过皮质类固醇或其他一些治疗得到控制。过敏性肺部改变可能会引起轻度呼吸困难,但不会致命。皮肤发绀和发黄是无害的副作用。至于肾脏和尿液中的磺胺结晶,在很大程度上,通过简单治疗即可避免。粒细胞缺乏症是柳氮磺胺吡啶治疗过程中罕见的并发症。在该药物使用的35年中,文献中仅发表了14例。其中3例死亡,但仅1例已知粒细胞缺乏症的治疗情况。可能存在未发表的病例,但根据我的经验,这个数字似乎不大。与许多其他药物(某些化疗药物和抗生素)相比,柳氮磺胺吡啶引起严重副作用的频率极低。

相似文献

1
Sulfasalazine: II. Some notes on the discovery and development of salazopyrin.柳氮磺胺吡啶:二、关于柳氮磺吡啶发现与研发的一些笔记
Am J Gastroenterol. 1988 May;83(5):497-503.
2
Sulfasalazine: I. An historical perspective.柳氮磺胺吡啶:一、历史回顾。
Am J Gastroenterol. 1988 May;83(5):487-96.
3
Salazopyrin in rheumatoid arthritis. 1978.柳氮磺胺吡啶治疗类风湿性关节炎。1978年。
Agents Actions. 1994 Dec;43(3-4):202-5. doi: 10.1007/BF01986689.
4
Salazopyrin-induced eosinophilic pneumonia.柳氮磺吡啶诱发的嗜酸性粒细胞性肺炎。
Respiration. 1980;39(2):119-20. doi: 10.1159/000194205.
5
Long term experience of salazopyrin EN in rheumatoid arthritis (RA).柳氮磺吡啶肠溶片治疗类风湿关节炎(RA)的长期经验
Scand J Rheumatol Suppl. 1987;64:37-47. doi: 10.3109/03009748709096720.
6
Salazopyrin-induced eosinophilic pneumonia.柳氮磺吡啶诱发的嗜酸性粒细胞性肺炎。
Respiration. 1985;47(2):158-60. doi: 10.1159/000194762.
7
[Pharmachem's salazopyrine in rheumatoid arthritis].
Vutr Boles. 1990;29(5):65-8.
8
[Granulocytopenia in treatment with salazopyrin].[柳氮磺胺吡啶治疗中的粒细胞减少症]
Tidsskr Nor Laegeforen. 1988 Nov 20;108(32):2982-3.
9
Clinical trials in ulcerative colitis: II. Historical review.溃疡性结肠炎的临床试验:II. 历史回顾。
Am J Gastroenterol. 1988 Mar;83(3):227-43.
10
[Experience with sulphasalazine (salazopyrin) in the treatment of rheumatoid arthritis].
Orv Hetil. 1986 Aug 24;127(34):2073-4, 2079-80.

引用本文的文献

1
Ulcerative colitis: Timeline to a cure.溃疡性结肠炎:治愈时间表。
World J Gastroenterol. 2025 Jul 14;31(26):108375. doi: 10.3748/wjg.v31.i26.108375.
2
Microbial Imidazole Propionate Affects Responses to Metformin through p38γ-Dependent Inhibitory AMPK Phosphorylation.微生物咪唑丙酸通过 p38γ 依赖性抑制 AMPK 磷酸化影响二甲双胍的反应。
Cell Metab. 2020 Oct 6;32(4):643-653.e4. doi: 10.1016/j.cmet.2020.07.012. Epub 2020 Aug 11.
3
[Nanna Svartz (1890-1986) : The first female professor of medicine in Sweden].[南娜·斯瓦尔茨(1890 - 1986):瑞典第一位医学女教授]
Z Rheumatol. 2017 Nov;76(9):813-819. doi: 10.1007/s00393-017-0389-y.
4
The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism.我们体内的微生物药剂师:对外源生物代谢的宏基因组学观点。
Nat Rev Microbiol. 2016 Apr;14(5):273-87. doi: 10.1038/nrmicro.2016.17. Epub 2016 Mar 14.
5
Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.克罗恩病:演变、表观遗传学以及微生物群靶向疗法的新作用
Curr Gastroenterol Rep. 2016 Mar;18(3):13. doi: 10.1007/s11894-016-0487-z.
6
Understanding and modulating mammalian-microbial communication for improved human health.理解并调节哺乳动物与微生物之间的交流以促进人类健康。
Annu Rev Pharmacol Toxicol. 2014;54:559-80. doi: 10.1146/annurev-pharmtox-011613-140007. Epub 2013 Oct 23.
7
Comparison between 5-aminosalicylic acid (5-ASA) and para-aminosalicylic acid (4-PAS) as potential protectors against Mn-induced neurotoxicity.5-氨基水杨酸(5-ASA)与对氨基水杨酸(4-PAS)对锰诱导神经毒性的潜在保护作用比较。
Biol Trace Elem Res. 2013 Apr;152(1):113-6. doi: 10.1007/s12011-012-9597-0. Epub 2013 Jan 15.
8
Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1.美沙拉嗪通过抑制 p21 激活激酶-1 调节细胞间黏附。
Biochem Pharmacol. 2013 Jan 15;85(2):234-44. doi: 10.1016/j.bcp.2012.10.026. Epub 2012 Nov 9.
9
Is mesalamine safe?美沙拉嗪安全吗?
Gastroenterol Hepatol (N Y). 2007 Nov;3(11):878-9.
10
Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis.老年类风湿关节炎患者使用传统和新型改善病情抗风湿药物的指南。
Drugs Aging. 2009;26(4):273-93. doi: 10.2165/00002512-200926040-00001.